| Primary |
| Drug Use For Unknown Indication |
21.2% |
| Thrombosis Prophylaxis |
15.2% |
| Product Used For Unknown Indication |
12.5% |
| Prophylaxis |
10.6% |
| Hypertension |
6.1% |
| Deep Vein Thrombosis |
4.4% |
| Pain |
4.0% |
| Pulmonary Embolism |
3.0% |
| Infection Prophylaxis |
2.9% |
| Anticoagulant Therapy |
2.8% |
| Atrial Fibrillation |
2.8% |
| Acute Coronary Syndrome |
2.7% |
| Thrombosis |
2.2% |
| Percutaneous Coronary Intervention |
1.8% |
| Thrombophlebitis |
1.5% |
| Chronic Obstructive Pulmonary Disease |
1.3% |
| Diabetes Mellitus |
1.2% |
| Pregnancy |
1.2% |
| Coronary Artery Disease |
1.2% |
| Hypercoagulation |
1.2% |
|
| Pulmonary Embolism |
21.9% |
| Liver Injury |
9.9% |
| Off Label Use |
7.1% |
| Exposure During Pregnancy |
6.5% |
| Thrombocytopenia |
6.2% |
| Death |
5.2% |
| Hepatitis |
4.6% |
| Hepatic Function Abnormal |
4.3% |
| Myocardial Infarction |
4.3% |
| Seroma |
4.3% |
| Drug Exposure During Pregnancy |
3.7% |
| Toxic Epidermal Necrolysis |
3.1% |
| Premature Baby |
2.8% |
| Coronary Artery Thrombosis |
2.5% |
| Thrombosis In Device |
2.5% |
| Transaminases Increased |
2.5% |
| Drug Ineffective |
2.2% |
| International Normalised Ratio Increased |
2.2% |
| Jaundice |
2.2% |
| Post Procedural Haemorrhage |
2.2% |
|
| Secondary |
| Product Used For Unknown Indication |
19.0% |
| Thrombosis Prophylaxis |
15.1% |
| Drug Use For Unknown Indication |
12.5% |
| Prophylaxis |
11.1% |
| Hypertension |
9.8% |
| Pain |
5.8% |
| Acute Coronary Syndrome |
3.0% |
| Supplementation Therapy |
2.9% |
| Chronic Obstructive Pulmonary Disease |
2.3% |
| Atrial Fibrillation |
1.9% |
| Diabetes Mellitus |
1.9% |
| Pulmonary Embolism |
1.9% |
| Fluid Replacement |
1.9% |
| Cardiac Failure |
1.8% |
| Diffuse Large B-cell Lymphoma |
1.7% |
| Psoas Abscess |
1.7% |
| Thrombosis |
1.6% |
| Acute Myocardial Infarction |
1.4% |
| Constipation |
1.4% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.4% |
|
| Toxic Epidermal Necrolysis |
20.9% |
| Thrombocytopenia |
12.0% |
| Pulmonary Embolism |
10.4% |
| Stevens-johnson Syndrome |
8.0% |
| Swelling Face |
6.4% |
| Myocardial Infarction |
4.0% |
| Rectal Haemorrhage |
3.6% |
| International Normalised Ratio Increased |
3.2% |
| Pancytopenia |
3.2% |
| Product Quality Issue |
2.8% |
| Renal Failure Acute |
2.8% |
| Thrombosis In Device |
2.8% |
| Upper Gastrointestinal Haemorrhage |
2.8% |
| Abscess |
2.4% |
| Epistaxis |
2.4% |
| Hepatic Function Abnormal |
2.4% |
| Hyponatraemia |
2.4% |
| In-stent Coronary Artery Restenosis |
2.4% |
| Tachycardia |
2.4% |
| Ventricular Tachycardia |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.6% |
| Drug Use For Unknown Indication |
17.1% |
| Prophylaxis |
8.8% |
| Hypertension |
7.5% |
| Pain |
6.4% |
| Thrombosis Prophylaxis |
5.0% |
| Multiple Myeloma |
4.2% |
| Non-small Cell Lung Cancer |
3.3% |
| Nausea |
2.8% |
| Diffuse Large B-cell Lymphoma |
2.8% |
| Atrial Fibrillation |
2.2% |
| Vomiting |
2.1% |
| Plasma Cell Myeloma |
2.1% |
| Constipation |
2.1% |
| Chronic Obstructive Pulmonary Disease |
1.7% |
| Back Pain |
1.6% |
| Rheumatoid Arthritis |
1.6% |
| Diabetes Mellitus |
1.5% |
| Colorectal Cancer |
1.3% |
| Anticoagulant Therapy |
1.3% |
|
| Vomiting |
12.3% |
| Pulmonary Embolism |
7.8% |
| Pyrexia |
7.7% |
| Pneumonia |
7.5% |
| Thrombocytopenia |
7.2% |
| Renal Failure Acute |
6.8% |
| Sepsis |
6.1% |
| Renal Failure |
5.1% |
| Urinary Tract Infection |
5.1% |
| Syncope |
4.0% |
| Death |
3.5% |
| General Physical Health Deterioration |
3.5% |
| Somnolence |
3.5% |
| Septic Shock |
3.4% |
| Neutropenia |
3.2% |
| Thrombosis |
2.9% |
| Toxic Epidermal Necrolysis |
2.8% |
| Respiratory Failure |
2.6% |
| Hypotension |
2.5% |
| Liver Function Test Abnormal |
2.5% |
|
| Interacting |
| Drug Use For Unknown Indication |
37.8% |
| Atrial Fibrillation |
10.9% |
| Thrombosis Prophylaxis |
7.1% |
| Acute Myocardial Infarction |
5.8% |
| Hypertension |
4.5% |
| Prophylaxis |
4.5% |
| Chronic Obstructive Pulmonary Disease |
3.8% |
| Skin Infection |
3.2% |
| Acute Coronary Syndrome |
2.6% |
| Anticoagulant Therapy |
2.6% |
| Cardioversion |
2.6% |
| Meniscus Operation |
2.6% |
| Product Used For Unknown Indication |
1.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.9% |
| Pulmonary Embolism |
1.9% |
| Atrial Flutter |
1.3% |
| Cardiac Failure Congestive |
1.3% |
| Decreased Appetite |
1.3% |
| Depression |
1.3% |
| Depressive Disorder |
1.3% |
|
| International Normalised Ratio Increased |
13.8% |
| Drug Interaction |
10.3% |
| Gastrointestinal Haemorrhage |
6.9% |
| Rash Maculo-papular |
6.9% |
| Subdural Haematoma |
6.9% |
| Upper Gastrointestinal Haemorrhage |
6.9% |
| Diverticulitis Intestinal Haemorrhagic |
3.4% |
| Haematuria |
3.4% |
| Haemoglobin Decreased |
3.4% |
| Haemorrhage |
3.4% |
| Hip Arthroplasty |
3.4% |
| Hypocoagulable State |
3.4% |
| Injection Site Induration |
3.4% |
| Intestinal Haemorrhage |
3.4% |
| Intracranial Haematoma |
3.4% |
| Muscle Haemorrhage |
3.4% |
| Myocardial Infarction |
3.4% |
| Oesophageal Ulcer |
3.4% |
| Potentiating Drug Interaction |
3.4% |
| Pruritus |
3.4% |
|
